Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Biological Markers

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5301/ijbm.5000291PMID 28777433
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells

  2019cited by this paper
• A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer

  2019cited by this paper
• Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge

  2019cited by this paper
• Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy

  2018cited by this paper
• Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells

  2015cited by this paper
• p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.

  2015cited by this paper
• BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• The fate of chemoresistance in triple negative breast cancer (TNBC)

  2015cited by this paper
• Triple negative breast cancer - BCL2 in prognosis and prediction. Review.

  2014cited by this paper
• Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.

  2014cited by this paper
• Hypoxia-mediated metastasis.

  2014cited by this paper
• The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis

  2013cited by this paper
• Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis

  2013cited by this paper
• Triple-negative breast cancer: molecular characterization and targeted therapies

  2013cited by this paper
• Hypoxia-induced signaling and its relevance in discovering biomarkers for cancer research

  2013cited by this paper
• Bcl-2, an Antiapoptotic Gene Indicator of Good Prognosis in Breast Cancer: The Paradox

  2013cited by this paper
• Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.

  2013cited by this paper
• Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer

  2012cited by this paper
• p53 Expression in Triple Negative Breast Carcinomas: Evidence of Age-Related and Racial Differences

  2012cited by this paper
• Assessing the clinical significance of tumor markers in common neoplasms.

  2012cited by this paper
• p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features.

  2011cited by this paper
• Targeting hypoxia in cancer therapy

  2011cited by this paper
• Tumor markers in breast cancer--evaluation of their clinical usefulness.

  2011cited by this paper
• Heterogeneity in breast cancer.

  2011cited by this paper
• Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) in Breast Cancer Patients

  2011cited by this paper
• Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

  2011cited by this paper
• p53 as a Marker of Prognosis in African-American Women with Breast Cancer

  2010cited by this paper
• Current treatment options in triple negative breast cancer.

  2010cited by this paper
• The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

  2010cited by this paper
• BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

  2010cited by this paper
• p53 as a specific prognostic factor in triple-negative breast cancer.

  2009cited by this paper
• Tumor hypoxia and malignant progression.

  2009cited by this paper
• Role of hypoxia in the hallmarks of human cancer

  2009cited by this paper
• Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation

  2009cited by this paper
• The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy

  2009cited by this paper
• Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models

  2007cited by this paper
• Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

  2007cited by this paper
• p53 in health and disease

  2007cited by this paper
• Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA.

  2007cited by this paper
• The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

  2006cited by this paper
• Cytological grading, apoptosis, and Bcl‐2 protein expression in breast cancer

  2002cited by this paper
• The Ki‐67 protein: From the known and the unknown

  2000cited by this paper

• Hallmarks of cancer in canine mammary tumors: Insights into a potential model for human triple-negative breast cancer.

  2026cites this paper
• Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy

  2025cites this paper
• Targeting Ferroptosis as the Achilles’ Heel of Breast Cancer: Mechanisms and Therapeutic Opportunities from a Comprehensive Systematic Review

  2025cites this paper
• Drug resistance in breast cancer: Mechanisms and strategies for management.

  2025cites this paper
• ESCO2 inhibition induces cell cycle arrest and apoptosis in breast cancer via the P53-CDK1 axis and the BAX/Bcl2/caspase signaling cascade

  2025cites this paper
• The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update.

  2024cites this paper
• In Vivo Detection of Multidrug-Resistance Related Proteins in Locally Advanced Breast Cancer Using 99mTc-MIBI SPECT/ CT Imaging: Correlation with Clinical Outcomes

  2024cites this paper
• A molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway

  2024influential citation
• Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment

  2024cites this paper
• Up-regulation of LPCAT1 is correlated with poor prognosis and promotes tumor progression in glioblastoma

  2024cites this paper
• Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.

  2023cites this paper
• Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens

  2023influential citation
• Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer

  2023cites this paper
• Hypoxia-induced autophagy in triple negative breast cancer: association with prognostic variables, patients’ survival and response to neoadjuvant chemotherapy

  2023cites this paper
• The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: systematic review and meta-analysis

  2023cites this paper
• Carbonic anhydrase IX-related tumoral hypoxia predicts worse prognosis in breast cancer: A systematic review and meta-analysis

  2023cites this paper
• Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA

  2023cites this paper
• Cyclooxygenase-2 and Bcl-2 expression in patients with triple-negative breast cancer

  2022cites this paper
• Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC

  2022cites this paper
• The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action

  2022cites this paper
• Identification of key pathways and genes in vestibular schwannoma using bioinformatics analysis.

  2022cites this paper
• Mitochondria dysfunction in circulating tumor cells

  2022cites this paper
• Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

  2022cites this paper
• Prognostic value of combining E-cadherin, p53, Bcl-2 and Bcl-xL expression and survival in Tunisian colorectal adenocarcinoma patients.

  2022cites this paper
• Natural Steroidal Lactone Induces G1/S Phase Cell Cycle Arrest and Intrinsic Apoptotic Pathway by Up-Regulating Tumor Suppressive miRNA in Triple-Negative Breast Cancer Cells

  2022cites this paper
• Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications

  2021cites this paper
• Evaluation of 12 Prognostic Biomarkers by 10 Years’ Disease-Free Survival and Cancer-Specific Survival Among Japanese Breast Cancer Patients

  2021cites this paper
• Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme

  2021cites this paper
• Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

  2021cites this paper
• Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer

  2021cites this paper
• Expression and clinicopathological significance of lipin‐1 in human breast cancer and its association with p53 tumor suppressor gene

  2020cites this paper
• Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis

  2020influential citation
• Identification of an autophagy-related gene signature for survival prediction in patients with cervical cancer

  2020cites this paper
• Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)

  2020cites this paper
• Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.

  2020cites this paper
• CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells

  2019cites this paper
• A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer

  2019cites this paper
• Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge

  2019cites this paper
• Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy

  2018cites this paper
• RESEARCH ARTICLE In Vivo Detection of Multidrug-Resistance Related Proteins in Locally Advanced Breast Cancer Using 99m Tc-MIBI SPECT/ CT Imaging: Correlation with Clinical Outcomes

  year unknowncites this paper